Fox News
Expand
Browse All Video
Watch Live

You're watching...

Will fast tracking cancer drugs put patients at risk?

Details

  • Description

    Dr. David Samadi weighs in

  • Duration 3:24
  • Date

Clips

Also in this playlist...

Editor's Picks

Auto-advance: ON

Auto-advance
View All

Transcript

This transcript is automatically generated

-- some call it a great -- on curing cancer new drug treatments are being fast tracked.

To patients that sounds good but could it put some patients at risk let's talk to doctor David's body he's a member of the Fox News medical -- team to Mauritania good morning historically it has entered to bring a new drug to market its cost a billion dollars and it's taken a decade now cost lots less and happens in no time.

But there's a good reason for it in -- and -- their last ten years what we've done is we've invested.

Billions of dollars in what would call human genetic project so we understand the disease.

Steve a lot better we understand the genetic components we know the bio markers you can target particular -- targeted therapy is an actual key -- that we use nowadays -- -- -- treating the entire system.

Giving chemotherapy that had a lot of side -- -- would not tolerated.

Did they get of this clinical trials now we can go for example there's -- unified ticket what would this new medication as out Corey.

It targets only that ALK -- specifically so certainly -- us along Kansas or certain patience.

Are good candidates and some are not and that's an incentive for a lot of drug companies.

To jump in and invest in it because they will know immediately within the 34 years -- the medication is gonna pan out what's gonna be -- -- trial and get out of that.

It sounds wonderful but is there a risk that they're not taking longer to get to Markkanen knocked -- -- -- bigger clinical trial started did it's an excellent question -- and they're going to be a lot of questions that goes on and answered but the FDA is obligated.

To even that followed these.

Drugs didn't -- -- during the market and if you know we know about decided takes.

And efficacy that's part of the phase one trial.

Because they have to recruit -- number of patients it can get in -- market faster but there's always a follow -- there and if there's really something.

But it may decide if -- to me pull those I think it's good news because a lot of these patients are devastated -- they have gone through surgery radiation -- nothing has worked.

It's the last stage of life and if you can extend the life.

This is a great race.

Early with -- lung cancer I mean that was one of the ones that seemed as though if you -- -- -- -- -- a death sentence and the idea that there is this new drug coming up it will just target those cells -- -- process.

-- you know something for those patients that are desperate.

Gays may mean years and years -- in their lifetime so I think that giving them a chance is a way to go.

And I think this also brings a lot of major companies that before the usable only for diabetes medications or cholesterol.

Big money drugs now they're gonna come in because they will know that they can have 3040 drugs in a short period so there's an incentive for bigger companies.

To get involved I think it's exciting news.

I think the keyword as a mission was targeted therapy that's a way of future and then we need to invest in this so I'm I'm just kind of curious it's all good news which would bring -- -- but it.

Is it happening faster because the government is cutting red tape or simply because.

They -- able to concoct a drug that is just more effective I think it's a little more effective less number of patient being recruited.

We understand the disease much better we understand the biology better.

And all of the work that we've done over last decade we can take advantage of it now.

It used to be only 3% of these medications coming out in the market -- -- about 15%.

So it's really exciting I think medicine is improving and you know something it's a great time to be a doctor and it's -- -- Notes there's another one for melanoma that's important to some of the people have gone on -- got his -- thanks so we have a lot of them coming up did -- based anti not a great day.

Load More